Use of Adipose Tissue Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

Hanan Jafar

Status and phase

Unknown

Phase 1

Conditions

Knee Osteoarthrosis

Treatments

Biological: Adipose tissue derived mesenchymal stem cell

Study type

Interventional

Funder types

Other

Identifiers

NCT02966951

ATKneeUJCTC

Details and patient eligibility

About

Adipose tissue derived Mesenchymal Stem cells (ATMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Full description

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to specific inclusion and exclusion criteria. These patients will be injected with Adipose Tissue derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Enrollment

10 estimated patients

Sex

All

Ages

42 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Severe KOA stage III or IV by Laurance & Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint.

Willing to participate by signing the informed consent

Exclusion criteria

Sublaxation beyond 20 degrees of the bones of the knee joint
Oral anticoagulants or heparin therapy
Heart failure or arrhythmia
Body Mass Index > 35
Uncontrolled Diabetes Mellitus.
Evidence of Infectious Diseases.
Active infection
Malignancy
Pregnancy
Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000.
Unreliable patients
Non-resident in Jordan